Targeted-theranostic nanoparticles induce anti-tumor immune response in lung cancer
High atomic number metal-based nanoparticles (NPs) enhance radiotherapy efficacy by improving tumor multimodal imaging and intensifying radiation dosage. AGuIX-Bi represents a theranostic NP comprising gadolinium and bismuth chelates grafted on a polysiloxane core. We hypothesize that modulating the surface of AGuIX-Bi with targeted peptides will enhance the therapeutic responses of radiation therapy. The cyclic Arg-Gly-Asp (cRGD) peptide has a high affinity to RGD-binding integrins overexpressed on various tumor cells, including lung cancer. In the present study, we introduced cRGD peptides onto the surface of AGuIX-Bi NPs using a PEG spacer to form an amide bond with the free amino functions present at the surface of the NPs. In vitro, AGuIX-Bi-cRGD showed enhanced internalization of NPs via integrin binding and increased radiosensitization. In murine Lewis lung carcinoma (LLC) tumors, AGuIX-Bi-cRGD exhibited increased accumulation and retention in tumors without causing systemic toxicity. Combined with fractionated irradiation, AGuIX-Bi-cRGD converted a “cold” LLC tumor microenvironment (TME) into a “hot” one by inducing the overexpression of the immunogenic cell death marker HMGB1 and increasing the density of tumor-infiltrating CD3+ CD8+ cytotoxic T cells and thereby delaying tumor growth and improving mice survival. Therefore, these results suggest a potential strategy for using targeted AGuIX-Bi-cRGD NPs to sensitize lung tumors to radiation and immunotherapies.
Authors
- Zeinaf Muradova
- Guillaume Bort (ORCID: https://orcid.org/0000-0001-9248-955X)
- Romy Guthier
- Sandrine Dufort
- Needa Brown
- François Lux (ORCID: https://orcid.org/0000-0003-1568-0240)
- Léna Carmès (ORCID: https://orcid.org/0000-0001-6646-3487)
- Éder José Guidelli (ORCID: https://orcid.org/0000-0002-4657-5112)
- Toby Morris (ORCID: https://orcid.org/0000-0002-5213-2182)
- Fabien Rossetti (ORCID: https://orcid.org/0000-0003-0998-6999)
- Sayeda Yasmin‐Karim
- Mileni Isikawa
- Ross Berbeco (ORCID: https://orcid.org/0000-0002-9076-4535)
- Olivier Tillement (ORCID: https://orcid.org/0000-0001-7166-6537)
- Michael Lavelle
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Central Florida (US)
- Brigham and Women's Hospital (US)
- Northeastern University (US)
- Centre National de la Recherche Scientifique (FR)
- Universidade de Ribeirão Preto (BR)
- University of Massachusetts Lowell (US)
- Inserm (FR)
- Universidade de São Paulo (BR)
- Institut Universitaire de France (FR)
- Université Paris Sciences et Lettres (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Universidade Cidade de São Paulo (BR)
- Dana-Farber Cancer Institute (US)
- Teem Photonics (France) (FR)
- Institut Lumière Matière (FR)
- Cedrat Technologies (France) (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12951-025-03542-4
- Citations
- 10
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 5.97
Funders
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- Centre National de la Recherche Scientifique
- National Cancer Institute